Ventures V. L.P. 5Am Sells 55,735 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA - Get Free Report) major shareholder Ventures V. L.P. 5Am sold 55,735 shares of the company's stock in a transaction that occurred on Friday, June 27th. The stock was sold at an average price of $6.91, for a total value of $385,128.85. Following the transaction, the insider owned 3,220,287 shares in the company, valued at $22,252,183.17. This trade represents a 1.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Entrada Therapeutics Stock Performance

Shares of Entrada Therapeutics stock traded up $0.16 during midday trading on Wednesday, hitting $7.27. The company had a trading volume of 126,328 shares, compared to its average volume of 134,381. Entrada Therapeutics, Inc. has a 52-week low of $6.59 and a 52-week high of $21.79. The stock has a market capitalization of $275.90 million, a P/E ratio of 8.98 and a beta of -0.11. The company has a 50 day moving average of $7.95 and a 200 day moving average of $10.83.

Entrada Therapeutics (NASDAQ:TRDA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 5.84% and a net margin of 14.39%. The business had revenue of $8.75 million for the quarter, compared to the consensus estimate of $10.98 million. Equities research analysts forecast that Entrada Therapeutics, Inc. will post 1.12 EPS for the current year.

Institutional Trading of Entrada Therapeutics

Several institutional investors have recently bought and sold shares of the company. Public Employees Retirement System of Ohio raised its holdings in Entrada Therapeutics by 6.2% in the fourth quarter. Public Employees Retirement System of Ohio now owns 17,259 shares of the company's stock worth $298,000 after buying an additional 1,000 shares during the last quarter. ExodusPoint Capital Management LP increased its position in shares of Entrada Therapeutics by 7.3% during the fourth quarter. ExodusPoint Capital Management LP now owns 16,453 shares of the company's stock valued at $284,000 after acquiring an additional 1,113 shares in the last quarter. WCG Wealth Advisors LLC raised its holdings in Entrada Therapeutics by 6.2% in the 4th quarter. WCG Wealth Advisors LLC now owns 24,030 shares of the company's stock worth $415,000 after acquiring an additional 1,406 shares during the last quarter. Martingale Asset Management L P lifted its position in Entrada Therapeutics by 4.0% in the 1st quarter. Martingale Asset Management L P now owns 40,163 shares of the company's stock valued at $363,000 after acquiring an additional 1,540 shares in the last quarter. Finally, Bank of America Corp DE lifted its position in Entrada Therapeutics by 4.9% in the 4th quarter. Bank of America Corp DE now owns 35,721 shares of the company's stock valued at $618,000 after acquiring an additional 1,660 shares in the last quarter. 86.39% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Wall Street Zen raised Entrada Therapeutics from a "sell" rating to a "hold" rating in a research note on Friday, June 27th. HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research report on Tuesday, May 20th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Entrada Therapeutics has an average rating of "Buy" and a consensus price target of $25.67.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.